DE69312567D1 - 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel - Google Patents

2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel

Info

Publication number
DE69312567D1
DE69312567D1 DE69312567T DE69312567T DE69312567D1 DE 69312567 D1 DE69312567 D1 DE 69312567D1 DE 69312567 T DE69312567 T DE 69312567T DE 69312567 T DE69312567 T DE 69312567T DE 69312567 D1 DE69312567 D1 DE 69312567D1
Authority
DE
Germany
Prior art keywords
hydrogen
formylpyridine
preparation
tumor agents
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69312567T
Other languages
English (en)
Other versions
DE69312567T2 (de
Inventor
Alan C Sartorelli
Tai-Shun Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of DE69312567D1 publication Critical patent/DE69312567D1/de
Application granted granted Critical
Publication of DE69312567T2 publication Critical patent/DE69312567T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69312567T 1992-05-13 1993-05-13 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel Expired - Fee Related DE69312567T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/882,154 US5281715A (en) 1992-05-13 1992-05-13 2-formylpyridine thiosemicarbazone compounds

Publications (2)

Publication Number Publication Date
DE69312567D1 true DE69312567D1 (de) 1997-09-04
DE69312567T2 DE69312567T2 (de) 1998-03-19

Family

ID=25379994

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69312567T Expired - Fee Related DE69312567T2 (de) 1992-05-13 1993-05-13 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel

Country Status (9)

Country Link
US (2) US5281715A (de)
EP (1) EP0570294B1 (de)
JP (1) JP3192027B2 (de)
AT (1) ATE156119T1 (de)
CA (1) CA2095881C (de)
DE (1) DE69312567T2 (de)
DK (1) DK0570294T3 (de)
ES (1) ES2108240T3 (de)
GR (1) GR3025207T3 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2065299C1 (ru) * 1994-07-15 1996-08-20 Акционерное общество закрытого типа "Олвик" Ноотропное и транквилизирующее средство
US5767134A (en) * 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US6040338A (en) * 1997-11-03 2000-03-21 Yale University N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents
EP1626718A4 (de) * 2003-05-01 2010-05-05 Panacea Pharmaceuticals Inc Verfahren zur behandlung von ischämischen erkrankungen
CA2527799A1 (en) * 2003-05-30 2004-12-16 Merck & Co., Inc. Methods for identifying modulators of kinesin activity
US20060194810A1 (en) * 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
WO2007035489A2 (en) * 2005-09-16 2007-03-29 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents
MD4126C1 (ro) * 2010-11-15 2012-04-30 Государственный Университет Молд0 N,N'-[4,4'-(perfluoro-1,4-fenilendioxi)-bis(4,1-fenilen)]-bis[2-(piridin-2-ilmetilen)hidrazincarbotioamidă] şi utilizarea ei în calitate de inhibitor al proliferării celulelor LNCaP ale cancerului prostatei
US20140271812A1 (en) 2013-03-14 2014-09-18 Panacea Pharmaceuticals Treatment for chemotherapy-induced cognitive impairment
US20140287021A1 (en) 2013-03-21 2014-09-25 Panacea Pharmaceuticals Treatment of chemotherapy-induced peripheral neuropathy
MD4349C1 (ro) * 2014-06-23 2015-12-31 Государственный Университет Молд0 Compusul N-(3-metoxifenil)-2-(piridin-2-ilmetilen)-hidrazincarbotioamidă - inhibitor al proliferării celulelor MeW-164 ale melanomului uman
MD4407C1 (ro) * 2015-04-29 2016-10-31 Государственный Университет Молд0 Inhibitor al celulelor HL-60 ale leucemiei umane mieloide în baza hidratului clorurii de bis[N-(prop-2-en-1-il)-2-(piridin-2-ilmetiliden)-hidrazincarbotioamid]-nichel(II)
MD4393C1 (ro) * 2015-09-04 2016-08-31 Государственный Университет Молд0 Inhibitor al celulelor HL-60 ale leucemiei umane mieloide în baza nitrato-[N′-(1-piridin-2-ilmetiliden)morfolin-4-carbotiohidrazido(1-)]cupru
MD4434C1 (ro) * 2015-10-09 2017-04-30 Государственный Университет Молд0 Utilizarea N'-[1-(2-piridil)etiliden]morfolin-4-carbotiohidrazidei în calitate de inhibitor al proliferării celulelor HL-60 ale leucemiei mieloide umane
MD4520C1 (ro) * 2016-12-16 2018-05-31 Государственный Университет Молд0 N-(4-butoxifenil)-2-(piridin-2-ilmetiliden)hidrazincarbotioamida în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8320308D0 (en) * 1983-07-28 1983-09-01 Wellcome Found Antiviral combinations

Also Published As

Publication number Publication date
US5721259A (en) 1998-02-24
DK0570294T3 (da) 1998-02-02
EP0570294B1 (de) 1997-07-30
ES2108240T3 (es) 1997-12-16
US5281715A (en) 1994-01-25
EP0570294A1 (de) 1993-11-18
GR3025207T3 (en) 1998-02-27
DE69312567T2 (de) 1998-03-19
JP3192027B2 (ja) 2001-07-23
ATE156119T1 (de) 1997-08-15
JPH06128230A (ja) 1994-05-10
CA2095881C (en) 2002-01-22
CA2095881A1 (en) 1993-11-14

Similar Documents

Publication Publication Date Title
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
ATE289602T1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
KR940007270B1 (en) Quinazoline derivatives
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE232520T1 (de) Imidazolidin-4-on derivate verwendbar als antikrebsmittel
NZ236034A (en) Pharmaceutical compositions containing imidazole derivatives; topical compositions for treating glaucoma
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
EP0192210A3 (en) New cephem compounds and processes for preparation thereof
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
DK0420121T3 (da) Antitumormiddel
MX9206930A (es) Nuevos compuestos
ATE160566T1 (de) Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel
ATE85056T1 (de) Tetracyclische indolderivate.
HK1067948A1 (en) Antitumor indolopyprolocarbazole derivative
ATE29133T1 (de) Troponon-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung.
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IL110369A0 (en) Pharmaceutical compositions for the prevention and/or treatment of gastrointestinal diseases including ulcer
HK34095A (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee